Drug interactions between Pradaxa and YSP Aspirin
| Results for the following 2 drugs: |
|---|
| Pradaxa (dabigatran) |
| YSP Aspirin (aspirin) |
Interactions between your selected drugs
aspirin ↔ dabigatran
Applies to:YSP Aspirin (aspirin) and Pradaxa (dabigatran)
MONITOR: Acetylsalicylic acid (ASA) may potentiate the risk of bleeding in patients treated with dabigatran etexilate. The pharmacologic effects of ASA that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation. Acetylsalicylic acid at dosages of 81 to 325 mg daily has been shown to increase the risk of bleeding when given concomitantly with dabigatran etexilate at dosages above those currently recommended (i.e., above 220 mg/day). In a phase 3 clinical trial of dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation, coadministration of oral antiplatelet agents including aspirin and clopidogrel increased the risk of bleeding by about two-fold. Furthermore, there is no evidence that the addition of ASA or clopidogrel to dabigatran, or its comparator warfarin, improved outcomes with respect to stroke.
MANAGEMENT: Caution is advised if dabigatran is used in combination with aspirin. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
